Synthesis and antimicrobial activity of novel 4-Hydroxy-2-quinolone analogs

Article abstract of DOI:10.3390/molecules25133059

Alkyl quinolone has been proven to be a privileged scaffold in the antimicrobial drug discovery pipeline. In this study, a series of new 4-hydroxy-2-quinolinone analogs containing a long alkyl side chain at C-3 and a broad range of substituents on the C-6 and C-7 positions were synthesized. The antibacterial and antifungal activities of these analogs against Staphylococcus aureus, Escherichia coli, and Aspergillus flavus were investigated. The structure-activity relationship study revealed that the length of the alkyl chain, as well as the type of substituent, has a dramatic impact on the antimicrobial activities. Particularly, the brominated analogs 3j with a nonyl side chain exhibited exceptional antifungal activities against A. flavus (half maximal inhibitory concentration (IC50) = 1.05 μg/mL), which surpassed that of the amphotericin B used as a positive control. The antibacterial activity against S. aureus, although not as potent, showed a similar trend to the antifungal activity. The data suggest that the 4-hydroxy-2-quinolone is a promising framework for the further development of new antimicrobial agents, especially for antifungal treatment.

Full text of DOI:10.3390/molecules25133059

molecules
Article
Synthesis and Antimicrobial Activity of Novel
-Hydroxy-2-quinolone Analogs
4
1
,†
2,†
2,†
Thitiphong Khamkhenshorngphanuch , Kittipat Kulkraisri , Alongkorn Janjamratsaeng ,
3
3
, Kanitta Manadee , Sarisa Na Pombejra 4 and
4
Napasawan Plabutong , Arsa Thammahong
5
,
Tanatorn Khotavivattana *
1
Department of General Education, Faculty of Science and Health Technology, Navamindradhiraj University,
Bangkok 10300, Thailand; thitiphong.kha@nmu.ac.th
2
3
4
5
Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand;
kittipatkulkraisri@gmail.com (K.K.); mekans89@gmail.com (A.J.)
Antimicrobial Resistance and Stewardship Research Unit, Department of Microbiology, Faculty of Medicine,
Chulalongkorn University, Bangkok 10330, Thailand; fah34405@gmail.com (N.P.); arsa.t@chula.ac.th (A.T.)
Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand;
noonkanitta@gmail.com (K.M.); sarisa.n@chula.ac.th (S.N.P.)
Center of Excellence in Natural Products Chemistry, Department of Chemistry, Faculty of Science,
Chulalongkorn University, Bangkok 10330, Thailand
*
Correspondence: tanatorn.k@chula.ac.th; Tel.: +66-2-218-7621
†
These authors contributed equally to this work.
ꢀ
ꢁꢂꢀꢃꢄꢅꢆꢇ
Academic Editor: Ana Estévez-Braun
Received: 15 June 2020; Accepted: 3 July 2020; Published: 4 July 2020
ꢀ
ꢁꢂꢃꢄꢅꢆ
Abstract: Alkyl quinolone has been proven to be a privileged scaffold in the antimicrobial drug
discovery pipeline. In this study, a series of new 4-hydroxy-2-quinolinone analogs containing a long
alkyl side chain at C-3 and a broad range of substituents on the C-6 and C-7 positions were synthesized.
The antibacterial and antifungal activities of these analogs against Staphylococcus aureus, Escherichia coli,
and Aspergillus flavus were investigated. The structure-activity relationship study revealed that the
length of the alkyl chain, as well as the type of substituent, has a dramatic impact on the antimicrobial
activities. Particularly, the brominated analogs 3j with a nonyl side chain exhibited exceptional
antifungal activities against A. flavus (half maximal inhibitory concentration (IC ) = 1.05 µg/mL),
50
which surpassed that of the amphotericin B used as a positive control. The antibacterial activity
against S. aureus, although not as potent, showed a similar trend to the antifungal activity. The data
suggest that the 4-hydroxy-2-quinolone is a promising framework for the further development of
new antimicrobial agents, especially for antifungal treatment.
Keywords: antibacterial; antifungal; 4-hydroxy-2-quinolinone; structure–activity relationship
1
. Introduction
The infection produced by microorganisms, such as bacteria or fungi, has long been considered as
one of the major global health concerns. Recently, the rapid emergence of drug-resistant pathogens has
caused a dramatic decrease in the effectiveness of the currently available medications [ ]. At present,
antimicrobial resistance causes 700,000 deaths annually, and the number is expected to rise to 10 million
in 2050 [ ]. As a result, the development of a new class of antimicrobial drugs is highly in demand as a
1
2
complement or replacement to existing antibiotics.
In the search for a new scaffold for antimicrobial drugs, 4-hydroxy-2-quinolone, a class of
heterocyclic compound, has shown great potential, as various analogs of 4-hydroxy-2-quinolone
including Roquinimex (Linomide), a synthetic immunomodulator [
3], have been reported to possess a
Molecules 2020, 25, 3059; doi:10.3390/molecules25133059
www.mdpi.com/journal/molecules

Molecules 2020, 25, 3059
2 of 12
wide range of biological activities such as antibacterial [4], antifungal [5], anticancer [6], antioxidant [7],
and so on. Over the past few decades, several attempts have been made to investigate the structure–
activity relationship of the antimicrobial activity of this scaffold; for instance, the derivatives of
4-hydroxy-2-quinolone bearing chalcones [
8], pyrimidines [9], pyrazoles [10], and thiadiazole [11]
(Figure 1a). Despite the extensive studies on the substituent pattern at the C-3 position, especially
with aromatic or heteroaromatic motifs, there is a limited number of studies on the effect of the
aliphatic side chain on the antimicrobial activity. According to a study on a similar scaffold such as
4
-hydroxycoumarin [12], or quinolone [13,14], it was found that the alkyl side chain plays a crucial role
in the antibacterial activity as reflected by the strong correlation between the length of the chain and
their bioactivity. In a previous study, it was found that the alkenyl side chain of 4-quinolones can form
hydrophobic interactions at a binding pocket within MurE ligase of Mycobacterium tuberculosis [15].
However, the mechanism of action of 4-hydroxy-2-quinolone remains unclear. To date, the effect
of substituents on the benzo-carbons of the 2-quinolone core structure has never been thoroughly
investigated for the antimicrobial activity; only the 6-nitro [16], 6,7-dimethoxy [17], and 5-hydroxy
and/or 6-carboxylic acid [18] analogs were investigated (Figure 1a). According to the development of
ciprofloxacin, a 4-quinolone drug popularly used until today, it was found that the introduction of
a fluorine atom at the C-6 position dramatically enhanced the antibacterial activity [19]. Moreover,
further study revealed that the type of substituents on the C-7 position led to an enormous impact on
their antimicrobial properties [20]. However, for the 4-hydroxy-2-quinolone core structure, the only
thorough investigation of the structure–activity relationship on the benzo-carbons was reported by
Jönsson and group in 2004, regarding their inhibitory effects on autoimmune disorders [21]. On the
other hand, the structure–activity relationship for antimicrobial activity remains unclear. Herein, we
report the diverted total synthesis of novel 4-hydroxy-2-quinolone analogs bearing an alkyl side chain
at C-3 and various types of substituents on C-6 and C-7 positions (Figure 1b). The obtained compounds
were then tested for their antibacterial and antifungal activities in order to obtain additional knowledge
on the structure–activity relationship of this promising scaffold.
Figure 1. 4-Hydroxy-2-quinolone analogs: (
a) Examples of the structure–activity relationship
investigated in previous works; ( ) novel 4-hydroxy-2-quinolone analogs bearing alkyl side chain at
b
C-3 and various types of substituents on C-6 and C-7 positions (this work).
2
. Results and Discussions
2
.1. Chemical Synthesis
The 4-hydroxy-2-quinolone analogs in this work were synthesized following a three-step protocol
starting from isatoic anhydrides with various substituents on the aromatic ring (Figure 2). First,
the alkylation of isatoic anhydrides was performed using either methyl iodide or ethyl iodide as

Molecules 2020, 25, 3059
3 of 12
the alkylating agents and N,N-diisopropylethylamine (DIPEA) as a base, leading to the formation
of N-alkylated isatoic anhydrides (1a 1g) in moderate to excellent yields [22]. Next, -ketoesters
2a and 2b) bearing long alkyl chains such as nonyl and tridecyl groups were synthesized by the
reaction between ethyl potassium malonate and the appropriate acid chlorides mediated by MgCl2
and triethylamine in good yields [23]. Finally, the condensation between 1a 1g and 2a or 2b was
achieved using NaH as a base, yielding the analogs of 4-hydroxy-2-quinolone (3a 3j) in relatively low
yields [24]. The structures of all the synthesized 4-hydroxy-2-quinolone analogs have been confirmed
–
β
(
–
–
1
13
by several spectroscopic techniques such as H NMR, C NMR, IR, and HRMS. It is worth noting that
these compounds show a characteristic pattern in 13C NMR: A signal at around
209 ppm indicating
δ
the carbonyl group on the side chain, and a set of signals at 174 and 161 ppm indicating C-4 and C-2 of
the quinolone ring, respectively.
Figure 2. Synthetic scheme of the 3-step protocol for the preparation of 4-hydroxy-2-quinolone
analogs (3a–3j).
In order to gain insight into the reason behind the poor yield of the final step, the reaction between 1d
and 2a for the synthesis of 3d was thoroughly investigated (Figure 3). The isolation and characterization
of byproducts revealed that, apart from the desired 4-hydroxy-2-quinolone analog 3d, which were
obtained in only 9%, two additional products also occurred: 1,4-Dihydroquinoline-3-carboxylate
analog 4d, which is a structural isomer of the desired product, and the 2-aminobenzoic acid 5d
were obtained in 17% and 51%, respectively. The generation of the two possible isomers, 3d and 4d
,
has been documented by Coppola and Hardtmann [25], demonstrating that the selectivity of such
transformation highly depends on the nature of the methylene species, which is the β-ketoester 2a
in this case. The formation of a large amount of 5d could be caused by the hydrolysis of the isatoic
anhydride 1d, hence indicating the presence of water in the reaction. Although several attempts were
made to exclude the moisture from the reaction, the yield of 3d was not significantly improved.
Figure 3. Synthesis of 3d from the reaction between 1d and 2a, generating 2 additional byproducts, 4d
and 5d.

Molecules 2020, 25, 3059
4 of 12
2
.2. Antimicrobial Activity and Structure–Activity Relationship
All the synthesized 4-hydroxy-2-quinolone analogs 3a
–
3j, as well as the isomer 4d, were
screened for their antifungal activity against a pathogenic fungus Aspergillus flavus, as well as
the antibacterial activity against a Gram-positive bacteria Staphylococcus aureus and a Gram-negative
bacteria Escherichia coli (Table 1). For the antifungal activity, compound 3a with no substituents
on the ring exhibited very low inhibition with a half maximal inhibitory concentration (IC ) of
50
7
0.97
±
3.71
µ
g/mL. The introduction of the substituents on the benzo-carbons led to significant
improvement in the potency, especially for the halogenated analogs 3d
,
3e, and 3f with up to fivefold
enhanced activity. This result is in line with a previous study reported by Huigens and group that the
introduction of halogen substituents, especially for bromine, to the quinoline core structure can lead to
higher antimicrobial activity, probably due to the metal(II)-dependent mechanism [26].
Table 1. Antifungal and antibacterial activity of 3a–3j and 4d.
Compound
Substituents
R 2
IC50 1 (µg/mL)
MIC 2 (µg/mL)
R 1
R 3
A. flavus
S. aureus
E. coli
3
a
tridecyl
tridecyl
tridecyl
tridecyl
tridecyl
tridecyl
tridecyl
nonyl
H
6-OCH3
7-Cl
7-NO2
6-Cl
6-Br
H
Me
Me
Me
Me
Me
Me
Et
70.97 ± 3.71
42.15 ± 18.61
14.72 ± 2.35
38.45 ± 5.51
37.08 ± 1.52
23.19 ± 3.19
9.48 ± 6.17
8.45 ± 1.59
4.60 ± 1.14
1.05 ± 1.31
23.44 ± 1.63
1.93 ± 1.04
ND
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
*
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
>1000
ND
3
b
3
c
3
d
3
e
3
f
3
g
3
h
H
Me
Me
Me
3
3
i
j
nonyl
6-Cl
6-Br
7-NO2 3
–
nonyl
tridecyl
**
>1000
ND
3
3
3
4
d
Me
–
4
AMB
CIP
–
–
5
–
–
0.835
0.0288
1
Half maximal inhibitory concentration (IC50) of the antifungal activity against A. flavus determined by broth
2
microdilution method, expressed as mean
activity against S. aureus and E. coli determined by broth microdilution method. All experiments were performed
±
SD; Minimum inhibitory concentration (MIC) of the antibacterial
3
in biological triplicates; The structure is based on the 1,4-dihydroquinoline-3-carboxylate scaffold (see Figure 3);
4
5
AMB = amphotericin B as a positive control for the antifungal activity; CIP = ciprofloxacin as a positive control
for the antibacterial activity; ND = No data. The MIC values of 3i (*) and 3j (**) were unclear; however, both
compounds showed inhibitory activities at the concentrations between 125–1000 and 125–500 µg/mL, respectively
(
Figure S3).
2
Replacing the methyl group with the ethyl group at the position R (3g) led to a dramatic
improvement in the inhibitory activity (IC50 = 9.48
for the replacement of the tridecyl with the nonyl group at the position R (3h) with the IC50 of
±
6.17
µ
g/mL). The same trend was observed
3
8
.45
±
1.59 µg/mL. This result suggests that an optimum size of these alkyl side chains is required,
presumably to fit into the hydrophobic pockets within microbial enzymes, as demonstrated earlier by
Bhakta and group [15]. Further enhancement in the antifungal activity was achieved when halogen
substituents were introduced at the benzo-carbon positions on the nonyl analog. The IC50 values of the
6
-chloro (3i) and 6-bromo (3j) nonyl analogs were 4.60
±
1.14 and 1.05
±
1.31 µg/mL, respectively, which
is almost 70 times higher than that of 3a. The inhibitory activity of 3j against A. flavus is even greater
than amphotericin B, the current fungicidal antifungal agent, with almost two times more effectiveness.
Lastly, the 1,4-dihydroquinoline-3-carboxylate analog 4d showed slightly higher activity compared to its
corresponding isomer 3d, which may suggest the possibility of further antifungal study on this scaffold.
For the antibacterial activity, it seems like these 4-hydroxy-2-quinolone analogs possess almost no
activity against both S. aureus and E. coli. Nevertheless, two compounds, 3i and 3j, exhibited significant
inhibitory activity against S. aureus. This result correlates well with the antifungal activity in which
these two analogs also showed the highest potency. Although the minimum inhibitory concentrations
(MICs) of 3i and 3j were unclear, both compounds demonstrated inhibitory effects on the bacterial
growth at concentrations between 125–1000 and 125–500 g/mL, respectively. It was interesting to
µ

Molecules 2020, 25, 3059
5 of 12
notice that the high concentration of compounds at 1000
µg/mL gave worse antibacterial results
than the medium concentrations (125–500 µg/mL; see Section 2 in the Supporting Information). This
phenomenon has been found in some quinolone-class antibiotics such as nalidixic acid. The survival
of bacteria at high concentrations of quinolones was explained by a decrease in reactive oxygen
species (ROS) level during exceeding quinolone concentrations [27]. The ROS accumulation is a key
mechanism of quinolone-mediated lethality [28], and this may relate to the antibacterial activity of
3i and 3j. However, the result of minimum bactericidal concentration (MBC) indicated that both 3i
and 3j exhibited a bacteriostatic effect rather than bactericidal activity (see Section 2 in the Supporting
Information). Taken together, the data suggest that the synthesized 4-hydroxy-2-quinolone analogs
could be further developed as promising antimicrobial agents especially for antifungal treatment.
As cellular structures of fungi and bacteria are largely different, based on our antimicrobial results,
these newly synthesized compounds may mainly target fungal molecules rather than bacterial ones.
This seems to be their outstanding property that is not found in other quinolone drugs, which are
primarily used as an antibacterial treatment.
3
. Materials and Methods
3
.1. General Experimental Procedures
All reagents and solvents were obtained from Sigma-Aldrich (St. Louis, MO, USA), TCI Chemicals
(
Tokyo, Japan), Fluorochem (Hadfield, Derbyshire, UK), and Merck (Darmstadt, Germany). All solvents
1
for column chromatography from RCI Labscan (Samutsakorn, Thailand) were distilled before use. H
and 13C NMR spectra were recorded on a Bruker Avance (400 MHz) (Bruker, Billerica, MA, USA),
country and Jeol Avance (500 MHz) (Jeol Ltd., Tokyo, Japan). Chemical shifts are reported as
in parts per million (ppm) relative to tetramethylsilane or the residual solvent signals in DMSO-d6
or CDCl as the internal standard for the NMR spectra. Data are reported as follows: Chemical shift
δ values
3
(
multiplicity, coupling constants in Hz, integrated intensity, assignment). Abbreviations of multiplicity
were as follows: s: Singlet, d: Doublet, t: Triplet, q: Quartet, m: Multiplet, br: Broad. High-resolution
mass spectra (HRMS) data were obtained with a Micro-TOF mass spectrometer (Bruker, Billerica,
MA, USA). IR spectra were recorded using the Thermo Scientific
™
Nicolet™ iS50 FTIR spectrometer
(
(
Thermo Fisher Scientific, Waltham, MA, USA) with an ATR module and are reported in wavenumber
cm ). Reactions were monitored by thin-layer chromatography (TLC) using aluminum Merck TLC
−1
plates coated with silica gel 60 F254. Normal-phase column chromatography was performed using
silica gel 60 (0.063–0.200 mm, 70–230 mesh ASTM, Merck, Darmstadt, Germany). Melting points were
measured using a melting point apparatus (Griffin) and are uncorrected.
3
.2. Synthesis of Compounds 1a–1g
Compounds 1a 1g were synthesized using a modified procedure [22]. Substituted isatoic
anhydride (1.0 equiv.) was added to a round-bottom flask. DIPEA (2.0 equiv.) and dimethylacetamide
DMAC) were added at room temperature and stirred for 10 min. The flask was fitted with a rubber
–
(
septum and purged with nitrogen gas. Appropriate alkyl halide (2.0 equiv.) was added dropwise,
◦
and the reaction was heated at 45 C for 2 h and monitored by thin-layer chromatography. Upon
completion, the reaction mixture was quenched with H O. The precipitate was filtered, washed with
2
H O, and concentrated in vacuo to give the product.
2
1-Methyl-2H-benzo[d] [1,3] oxazine-2,4(1H)-dione (1a): Isatoic anhydride (2.00 g, 12.3 mmol), methyl
iodide (1.60 mL, 24.6 mmol), and DMAC (13 mL) were used to give the title compound (1.75 g, 81%
1
yield) as an off-white solid. H NMR (400 MHz, DMSO)
1
1
δ
8.01 (d, J = 7.7 Hz, 1H), 7.86 (t, J = 7.9 Hz,
13
H), 7.44 (d, J = 8.4 Hz, 1H), 7.34 (t, J = 7.6 Hz, 1H), 3.47 (s, 3H); C NMR (101 MHz, DMSO)
47.71, 142.18, 137.15, 129.28, 123.54, 114.80, 111.49, 31.63 [29].
δ 158.95,

Molecules 2020, 25, 3059
6 of 12
6
-Methoxy-1-methyl-2H-benzo[d] [1,3] oxazine-2,4(1H)-dione (1b): 5-Methoxyisatoic anhydride (290 mg,
1
.5 mmol), methyl iodide (186
µ
L, 3.0 mmol), and DMAC (3 mL) were used to give the title compound
1
(191 mg, 61% yield) as a light-green solid. H NMR (400 MHz, DMSO)
δ
7.52–7.34 (m, J = 17.7, 8.9 Hz,
3
1
H), 3.83 (s, 3H), 3.45 (s, 3H); 13C NMR (101 MHz, DMSO)
16.54, 112.12, 110.88, 55.80, 31.71 [30].
δ 158.84, 155.17, 147.52, 136.31, 124.99,
7-Chloro-1-methyl-2H-benzo[d] [1,3] oxazine-2,4(1H)-dione (1c): 4-Chloroisatoic anhydride (300 mg,
1
.5 mmol), methyl iodide (186
µ
L, 3.0 mmol), and DMAC (2 mL) were used to give the title compound
1
(
260 mg, 81% yield) as a white solid. H NMR (400 MHz, DMSO)
δ
8.00 (d, J = 8.4 Hz, 1H), 7.58 (s, 1H),
13
7
.39 (d, J = 8.3 Hz, 1H), 3.46 (s, 3H); C NMR (101 MHz, DMSO)
δ
158.27, 143.39, 141.89, 131.01, 130.73,
1
23.64, 114.86, 110.59, 31.91 [31].
1
-Methyl-7-nitro-2H-benzo[d][1,3] oxazine-2,4(1H)-dione (1d): 4-Nitroisatoic anhydride (312 mg, 1.5 mmol),
methyl iodide (186
µ
L, 3.0 mmol), and DMAC (2 mL) were used to give the title compound (306 mg,
1
8
1
1
1% yield) as a yellow solid. H NMR (400 MHz, DMSO)
H), 8.06 (dd, J = 8.5, 1.8 Hz, 1H), 3.56 (s, 3H); 13C NMR (101 MHz, DMSO)
δ 157.87, 152.43, 147.33,
δ
8.25 (d, J = 8.5 Hz, 1H), 8.12 (d, J = 1.5 Hz,
43.06, 131.13, 117.50, 110.82, 109.84, 32.08 [30].
6-Chloro-1-methyl-2H-benzo[d] [1,3] oxazine-2,4(1H)-dione (1e): 5-Chloroisatoic anhydride (297 mg,
1
.5 mmol), methyl iodide (186
µ
L, 3.0 mmol), and DMAC (2 mL) were used to give the title compound
1
(
258 mg, 81% yield) as a white solid. H NMR (400 MHz, CDCl )
δ
8.22 (d, J = 2.4 Hz, 1H), 7.82 (dd,
157.43, 147.61, 140.72,
3
J = 8.9, 2.5 Hz, 1H), 7.36 (s, 1H), 3.68 (s, 3H); 13C NMR (101 MHz, CDCl3)
δ
1
37.37, 131.56, 130.16, 115.59, 113.11, 32.20 [32].
6-Bromo-1-methyl-2H-benzo[d] [1,3] oxazine-2,4(1H)-dione (1f): 5-Bromoisatoic anhydride (363 mg,
1
.5 mmol), methyl iodide (186
µ
L, 3.0 mmol), and DMAC (2 mL) were used to give the title compound
1
(
368 mg, 96% yield) as a brown solid. H NMR (400 MHz, CDCl )
δ
8.26 (d, J = 2.3 Hz, 1H), 7.85 (dd,
157.31, 147.59,
3
J = 8.8, 2.3 Hz, 1H), 7.08 (d, J = 8.9 Hz, 1H), 3.57 (s, 3H); 13C NMR (101 MHz, CDCl3)
δ
1
41.17, 140.19, 133.20, 117.06, 115.80, 113.42, 32.17 [29].
1
-Ethyl-2H-benzo[d] [1,3] oxazine-2,4(1H)-dione (1g): Isatoic anhydride (245 mg, 1.3 mmol), ethyl iodide
(
240
µ
L, 3.0 mmol), and DMAC (2 mL) were used to give the title compound (246 mg, 48% yield) as an
1
off-white solid. H NMR (400 MHz, DMSO)
(
(
δ 8.02 (d, J = 7.8 Hz, 1H), 7.85 (t, J = 7.9 Hz, 1H), 7.50
d, J = 8.5 Hz, 1H), 7.33 (t, J = 7.6 Hz, 1H), 4.06 (q, J = 7.0 Hz, 2H), 1.23 (t, J = 7.1 Hz, 3H); 13C NMR
101 MHz, DMSO) δ 145.61, 141.10, 137.23, 129.61, 123.47, 122.62, 114.58, 111.75, 31.67, 11.86 [33].
3
.3. Synthesis of Compounds 2a and 2b
Compounds 2a and 2b were synthesized using a modified procedure [23]. Ethyl potassium
malonate (2.0 equiv.), MgCl (3.0 equiv.), and NEt (3.0 equiv.) were added to a round-bottom flask.
2
3
The flask was fitted with a rubber septum and purged with nitrogen gas, and dry MeCN was then
added. The mixture was stirred at room temperature for 2 h, appropriate acid chloride (1.0 equiv.)
◦
was then added dropwise at 0 C, and the mixture was stirred overnight at room temperature. Upon
completion, the reaction mixture was extracted with CH Cl and H O. The combined organic layers
2
2
2
were washed with brine, dried over anh. Na SO , filtered, and then concentrated in vacuo. The crude
2
4
mixture was purified by silica gel column chromatography to give the product.
Ethyl 3-oxohexadecanoate (2a): Ethyl potassium malonate (6.30 g, 37.0 mmol), myristoyl chloride (4.80 mL,
1
7.7 mmol), and MeCN (84 mL) were used to give the title compound (4.24 g, 80% yield) as a light-yellow
1
oil. H NMR (400 MHz, CDCl )
δ 4.19 (q, J = 7.1 Hz, 2H), 3.42 (s, 2H), 2.52 (t, J = 7.4 Hz, 2H), 1.65–1.52
3
13
(
m, 3H), 1.24 (s, 20H), 0.89–0.85 (m, J = 6.6 Hz, 5H); C NMR (101 MHz, CDCl3)
δ
203.11, 167.43, 89.09,
6
1.46, 49.45, 43.19, 35.20, 33.97, 32.05, 29.80, 29.77, 29.72, 29.57, 29.48, 29.37, 24.86, 22.81, 14.22 [34].
Ethyl 3-oxododecanoate (2b): Ethyl potassium malonate (1.7 g, 10 mmol), decanoyl chloride (1.6 mL,
.5 mmol), and MeCN (23 mL) were used to give the title compound (1.271 g, 75% yield) as a light-yellow
7

Molecules 2020, 25, 3059
7 of 12
1
oil. H NMR (400 MHz, CDCl )
(
δ
4.18 (dt, J = 6.8, 5.4 Hz, 2H), 3.42 (s, 2H), 2.52 (t, J = 7.4 Hz, 2H), 1.60
3
dd, J = 21.9, 14.9 Hz, 3H), 1.44–1.12 (m, 14H), 0.87 (t, J = 6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3)
δ
6
1.45, 49.45, 43.18, 35.20, 31.99, 29.53, 29.48, 29.37, 29.19, 29.16, 26.39, 23.62, 22.78, 14.23 [35].
3
.4. Synthesis of Compounds 3a–3j, 4d, and 5d
Compounds 3a
60% in mineral oil) was added to a round-bottom flask and washed with hexane 3 times. The flask was
fitted with a rubber septum and purged with nitrogen gas, and N-alkyl substituted isatoic anhydride
1a 1g), -ketoester (2a 2b), and dry DMF were then added. The mixture was stirred overnight at
–3j, 4d, and 5d were synthesized using a modified procedure [24]. Sodium hydride
(
(
–
β
–
room temperature. Upon completion, the reaction mixture was quenched with H O. The resulting
2
mixture was extracted with ethyl acetate (EtOAc). The combined organic layers were washed with
brine, dried over anh. Na SO , filtered, and then concentrated in vacuo. The crude mixture was
2
4
purified by silica gel column chromatography to give the products.
4
-Hydroxy-1-methyl-3-tetradecanoylquinolin-2(1H)-one (3a): 1a (354 mg, 1.0 mmol), 2a (596 mg, 1.0 mmol),
NaH (60 mg, 1.5 mmol), and DMF (4 mL) were used and purified by silica gel column chromatography
1
(
eluent: 5% EtOAc in hexanes) to give the title product (186 mg, 24% yield) as an off-white solid. H
NMR (400 MHz, CDCl3)
(
(
δ
8.23 (d, J = 6.9 Hz, 1H), 7.72–7.66 (m, 1H), 7.30 (d, J = 8.6 Hz, 1H), 7.32–7.27
m, 1H), 3.65 (s, 3H), 3.29 (t, J = 7.4 Hz, 2H), 1.76–1.67 (m, 2H), 1.57 (s, 2H), 1.28 (d, J = 16.6 Hz, 18H), 0.88
t, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3)
209.71, 174.28, 161.65, 152.68, 141.81, 134.90, 126.34,
24.24, 122.15, 115.84, 114.29, 57.11, 43.11, 32.08, 29.84, 29.80, 29.72, 29.71, 29.54, 29.51, 29.29, 24.49,
δ
1
2
1
2.84, 14.25; IR (neat): 2916.00, 2848.35, 1651.82, 1624.97, 1590.46, 1557.51, 1502.15, 1463.21, 1427.31,
409.30, 1339.12, 1303.63, 1280.61, 1251.95, 1198.68, 1171.19, 1061.74, 1039.80, 1030.70, 980.98; HRMS
+
+
+
◦
(ESI ): m/z calcd for C H NO Na [M− H + 2Na] 430.2329, found 430.2319; Mp: 70.0–70.8 C.
24
34
3
2
4
-Hydroxy-6-methoxy-1-methyl-3-tetradecanoylquinolin-2(1H)-one (3b): 1b (62 mg, 0.30 mmol), 2a (90 mg,
0
.30 mmol), NaH (18 mg, 0.45 mmol), and DMF (1 mL) were used and purified by silica gel column
chromatography (eluent: EtOAc/hexanes = 1:4) to give the title product (21 mg, 22% yield) as a
1
light-green solid. H NMR (400 MHz, CDCl )
δ
7.62 (d, J = 2.8 Hz, 1H), 7.31 (dd, J = 9.2, 2.9 Hz, 1H),
3
7
2
1
2
.25 (d, J = 13.9 Hz, 1H), 3.90 (s, 3H), 3.64 (s, 3H), 3.31 (t, J = 7.4 Hz, 2H), 1.75–1.70 (m, 2H), 1.27 (s,
0H), 0.89 (t, J = 6.7 Hz, 3H); 13C NMR(101 MHz, CDCl3)
209.84, 173.65, 161.27, 154.90, 152.80, 136.63,
24.67, 122.63, 115.87, 106.59, 102.05, 89.45, 55.95, 43.11, 32.08, 29.84, 29.80, 29.72, 29.71, 29.54, 29.50,
9.40, 24.49, 22.84, 14.25. IR (neat): 2916.19, 2849.20, 1647.85, 1592.93, 1572.55, 1505.80, 1466.05, 1452.89,
413.22, 1382.45, 1357.95, 1339.80, 1236.89, 1196.42, 1177.76, 1148.43, 1059.87, 1034.63, 1004.25, 857.67,
δ
1
8
6
+
+
+
21.28; HRMS (ESI ): m/z calcd for C H NO Na [M
−
H + 2Na] 460.2434, found 460.2427; Mp:
25
36
4
2
◦
7.8–71.5 C.
-Chloro-4-hydroxy-1-methyl-3-tetradecanoylquinolin-2(1H)-one (3c): 1c (127 mg, 0.60 mmol), 2a (150 mg,
.50 mmol), NaH (30 mg, 0.75 mmol), and DMF (1 mL) were used and purified by silica gel column
7
0
chromatography (eluent: 4% EtOAc in hexanes) to give the title product (26 mg, 12% yield) as a white
1
solid. H NMR (400 MHz, CDCl )
δ
8.15 (d, J = 8.6 Hz, 1H), 7.30 (d, J = 1.2 Hz, 1H), 7.22 (dd, J = 8.6,
3
1
.5 Hz, 1H), 3.61 (s, 3H), 3.27 (t, J = 7.4 Hz, 2H), 1.75–1.65 (m, 2H), 1.26 (s, 20H), 0.88 (t, J = 6.8 Hz, 3H);
13
C NMR (101 MHz, CDCl3)
05.60, 97.19, 86.07, 43.04, 32.08, 29.83, 29.79, 29.71, 29.68, 29.51, 29.41, 24.43, 22.83, 14.24; IR (neat):
916.03 2852.38, 1644.46, 1609.69, 1556.11, 1473.10, 1443.16, 1421.20, 1378.16, 1343.22, 1320.45, 1264.80,
δ 209.63, 173.81, 171.52, 161.49, 142.53, 141.38, 127.71, 122.72, 114.36, 105.86,
1
2
1
+
−
227.80, 1203.14, 1099.25, 1031.70, 966.59, 891.66, 841.66; HRMS (ESI ): m/z calcd for C H ClNO
24 33 3
−
◦
[M − H] 418.2154, found 418.2148; Mp: 103.4–103.9 C.
4-Hydroxy-1-methyl-7-nitro-3-tetradecanoylquinolin-2(1H)-one (3d), ethyl 1-methyl-7-nitro-4-oxo-2-
tridecyl-1,4-dihydroquinoline-3-carboxylate (4d), and 2-(methylamino)-4-nitrobenzoic acid (5d): 1d
134 mg, 0.60 mmol), 2a (150 mg, 0.50 mmol), NaH (30 mg, 0.75 mmol), and DMF (1 mL) were used
and purified by silica gel column chromatography (eluent: 4% EtOAc in hexanes) to give 3d (18 mg,
(

Molecules 2020, 25, 3059
8 of 12
9
% yield) as a yellow solid, 4d (40 mg, 17% yield) as a yellow-green solid, and 5d (50 mg, 51% yield) as
an orange solid, respectively.
1
3
d
: H NMR (400 MHz, CDCl )
δ
8.40 (d, J = 8.8 Hz, 1H), 8.17 (d, J = 1.8 Hz, 1H), 8.05 (dd, J = 8.7,
3
1
0
1
2
.8 Hz, 1H), 3.72 (s, 3H), 3.30 (t, J = 7.4 Hz, 2H), 1.71 (d, J = 7.3 Hz, 2H), 1.43–1.37 (m, 2H), 1.26 (s, 18H),
.88 (t, J = 6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3)
210.00, 172.68, 161.20, 141.89, 132.97, 128.08,
20.13, 116.14, 111.27, 110.23, 109.66, 52.31, 46.67, 43.24, 32.07, 29.82, 29.79, 29.68, 29.65, 29.50, 29.45,
4.31, 22.83, 14.24. IR (neat): 2920.29, 2852.03, 1630.31, 1605.71, 1563.83, 1519.60, 1470.98, 1346.51,
δ
+
1
321.48, 1278.93, 1277.83, 1104.60, 1033.57, 986.91, 888.50, 828.10, 813.47; HRMS (ESI ): m/z calcd for
−
−
◦
C H N O [M − H] 429.2395, found 429.2384; Mp: 156.3–168.4 C.
24
33
2
5
1
4
d
: H NMR (400 MHz, CDCl )
δ
8.55 (d, J = 8.7 Hz, 1H), 8.45 (s, 1H), 8.13 (d, J = 8.7 Hz, 1H), 4.41 (d,
J = 7.1 Hz, 2H), 3.86 (s, 3H), 2.87–2.71 (m, 2H), 1.71 (d, J = 7.0 Hz, 2H), 1.44 (d, J = 7.0 Hz, 2H), 1.39 (t,
J = 7.1 Hz, 3H), 1.25 (s, 18H), 0.87 (t, J = 6.7 Hz, 3H); (101 MHz, CDCl3) 173.30, 166.95, 154.84, 150.20,
41.36, 129.85, 129.18, 120.11, 117.84, 112.11, 61.87, 35.23, 32.60, 32.02, 29.79, 29.76, 29.73, 29.67, 29.56,
3
δ
1
2
9.44, 29.28, 29.04, 22.79, 14.37. IR (neat): 2917.90, 2852.52, 1726.40, 1597.66, 1518.79, 1496.50, 1464.33,
+
1
384.73, 1345.48, 1214.81, 1135.89, 1105.59, 1037.28, 1022.98, 890.49, 855.73, 825.02; HRMS (ESI ): m/z
+
+
◦
calcd for C H N O Na [M + Na] 481.2678, found 481.2676; Mp: 92.6–95.2 C.
26
38
2
5
1
5
3
d
: H NMR (400 MHz, DMSO)
δ
7.99 (d, J = 8.6 Hz, 1H), 7.37 (d, J = 1.7 Hz, 1H), 7.33–7.27 (m, 1H),
168.63, 151.78, 151.39, 133.26, 115.08, 107.65,
.46 (s, 1H), 2.91 (s, 3H); 13C NMR (101 MHz, DMSO)
δ
1
04.81, 29.32 [36].
6-Chloro-4-hydroxy-1-methyl-3-tetradecanoylquinolin-2(1H)-one (3e): 1e (159 mg, 0.75 mmol), 2a (150 mg,
0
.50 mmol), NaH (30 mg, 0.75 mmol), and DMF (1 mL) were used and purified by silica gel column
chromatography (eluent: 5% EtOAc in hexanes) to give the title product (60 mg, 28% yield) as a white
1
solid. H NMR (400 MHz, CDCl )
δ 8.21 (d, J = 2.4 Hz, 1H), 7.65 (dd, J = 9.0, 2.5 Hz, 1H), 7.29 (d,
3
J = 3.2 Hz, 1H), 3.66 (s, 3H), 3.31 (t, J = 7.4 Hz, 2H), 1.73 (dt, J = 14.9, 7.5 Hz, 2H), 1.64 (s, 2H), 1.42
13
(
d, J = 8.8 Hz, 2H), 1.28 (s, 16H), 0.91 (t, J = 6.8 Hz, 3H); C NMR (101 MHz, CDCl3) δ 209.76, 173.14,
1
61.26, 140.24, 134.85, 130.85, 128.03, 125.56, 116.91, 115.86, 65.84, 57.63, 47.37, 43.11, 32.07, 29.83, 29.79,
2
9.70, 29.68, 29.50, 29.46, 24.39, 22.83, 14.24. IR (neat): 2919.88, 2847.72, 1651.26, 1635.04, 1610.19,
+
1
551.49, 1463.26, 1402.46, 1293.20, 1206.95, 1093.57, 1052.40, 955.38, 897.40, 819.76, 812.24; HRMS (ESI ):
−
−
◦
m/z calcd for C H ClNO [M − H] 418.2154, found 418.2149; Mp: 73.5–80.0 C.
24
33
3
6
-Bromo-4-hydroxy-1-methyl-3-tetradecanoylquinolin-2(1H)-one (3f): 1f (192 mg, 0.75 mmol), 2a (150 mg,
0
.50 mmol), NaH (30 mg, 0.75 mmol), and DMF (1 mL) were used and purified by silica gel column
chromatography (eluent: 5% EtOAc in hexanes) to give the title product (63 mg, 27% yield) as a
1
light-brown solid. H NMR (400 MHz, CDCl )
δ 8.31 (d, J = 2.1 Hz, 1H), 7.74 (dd, J = 9.0, 2.3 Hz, 1H),
3
7
.17 (d, J = 9.0 Hz, 1H), 3.61 (s, 3H), 3.27 (t, J = 7.4 Hz, 2H), 1.70 (dt, J = 14.9, 7.4 Hz, 2H), 1.40 (s, 2H),
13
1
1
2
.25 (s, 18H), 0.88 (d, J = 6.5 Hz, 3H); C NMR (101 MHz, CDCl3)
37.54, 128.63, 117.29, 116.07, 115.17, 106.28, 61.69, 56.13, 55.98, 43.09, 32.06, 29.82, 29.78, 29.69, 29.67,
9.49, 29.41, 24.37, 22.82, 14.23. IR (neat): 2919.92, 2851.49, 1644.22, 1606.11, 1551.76, 1494.12, 1464.02,
δ 209.71, 173.06, 161.21, 140.61,
+
1429.07, 1413.33, 1317.00, 1292.07, 1252.78, 1149.12, 1062.14, 1000.11, 821.17, 807.49; HRMS (ESI ): m/z
−
−
◦
calcd for C H BrNO [M − H] 462.1649, found 462.1657; Mp: 73.2–75.0 C.
24
33
3
1
-Ethyl-4-hydroxy-3-tetradecanoylquinolin-2(1H)-one (3g): 1g (144 mg, 0.75 mmol), 2a (150 mg, 0.50 mmol),
NaH (30 mg, 0.75 mmol), and DMF (1 mL) were used and purified by silica gel column chromatography
1
(
eluent: 5% EtOAc in hexanes) to give the title product (16 mg, 8% yield) as an off-white solid. H
NMR (400 MHz, CDCl3)
.23 (d, J = 7.3 Hz, 1H), 4.60–4.00 (m, 2H), 3.70–3.02 (m, 3H), 1.70 (dt, J = 23.8, 11.5 Hz, 2H), 1.41–1.10
m, 23H), 0.87 (t, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3)
209.71, 174.07, 161.16, 140.88, 134.83,
33.69, 126.53, 123.77, 121.92, 116.00, 114.14, 105.95, 43.16, 37.22, 32.07, 29.83, 29.79, 29.71, 29.51, 29.50,
δ 8.24 (dd, J = 8.0, 1.3 Hz, 1H), 7.71–7.62 (m, 1H), 7.31 (d, J = 8.6 Hz, 1H),
7
(
δ
1
2
7
−
+
9.18, 24.41, 22.83, 14.24, 12.94; m/z calcd for C H NO [M + 3H] 402.3008, found 402.3003; Mp:
4.1–75.5 C.
25
37
3
◦

Molecules 2020, 25, 3059
9 of 12
3
-Decanoyl-4-hydroxy-1-methylquinolin-2(1H)-one (3h): 1a (266 mg, 1.50 mmol), 2b (365 mg, 1.50 mmol),
NaH (90 mg, 2.25 mmol), and DMF (1 mL) were used and the crude product was purified by silica gel
column chromatography (eluent: 5% EtOAc in Hexanes) to give the title product (35 mg, 7% yield) as a
1
light-yellow oil. H NMR (500 MHz, CDCl )
δ 8.25–8.08 (m, 1H), 7.65 (d, J = 7.1 Hz, 1H), 7.24 (dd,
3
J = 16.2, 8.1 Hz, 2H), 3.61 (dd, J = 15.7, 1.4 Hz, 3H), 3.25 (d, J = 7.1 Hz, 2H), 1.68 (d, J = 6.2 Hz, 2H), 1.25
s, 13H), 0.84 (d, J = 6.2 Hz, 3H); 13C NMR (126 MHz, CDCl3)
209.70, 174.24, 161.64, 141.75, 134.94,
26.31, 122.19, 115.78, 114.32, 105.95, 43.17, 32.07, 29.73, 29.70, 29.54, 29.48, 29.30, 24.46, 22.85, 14.29; m/z
(
δ
1
−
−
◦
calcd for C H NO [M − H] 374.1708, found 374.1711; Mp: 65.0–69.1 C.
20
27
3
6-Chloro-3-decanoyl-4-hydroxy-1-methylquinolin-2(1H)-one (3i): 1e (80 mg, 0.38 mmol), 2b (92 mg,
0.38 mmol), NaH (22.8 mg, 0.57 mmol), and DMF (1 mL) were used and purified by silica gel column
chromatography (eluent: 5% EtOAc in Hexanes) to give the title product (31 mg, 22% yield) as an
1
off-white solid. H NMR (500 MHz, CDCl )
3
δ 8.57–7.97 (m, 1H), 7.82–7.43 (m, 1H), 7.53–6.99 (m, 1H),
3
.63 (d, J = 13.9 Hz, 3H), 3.34–3.16 (m, 2H), 1.71 (s, 2H), 1.29 (s, 13H), 0.88 (d, J = 6.1 Hz, 3H). 13
C
NMR (126 MHz, CDCl3) δ 209.80, 173.15, 161.29, 140.23, 134.90, 128.05, 125.58, 116.89, 115.92, 107.49,
−
−
H]
1
3
06.33, 43.19, 32.08, 29.72, 29.70, 29.51, 29.49, 24.39, 22.86, 14.30; m/z calcd for C H ClNO [M
62.1523, found 362.9271; Mp: 79.5–81.0 C.
−
20
25
3
◦
6-Bromo-3-decanoyl-4-hydroxy-1-methylquinolin-2(1H)-one (3j): 1f (139 mg, 0.60 mmol), 2b (150 mg,
0
.60 mmol), NaH (36 mg, 0.90 mmol), and DMF (1 mL) were used and purified by silica gel column
chromatography (eluent: 5% EtOAc in Hexanes) to give the title product (18 mg, 7% yield) as a
1
light-brown solid. H NMR (500 MHz, CDCl )
δ 8.40 (d, J = 15.5 Hz, 1H), 7.80 (d, J = 8.6 Hz, 1H),
3
7
(
1
.24 (d, J = 8.9 Hz, 1H), 3.69 (d, J = 15.0 Hz, 3H), 3.34 (d, J = 7.4 Hz, 2H), 1.78 (d, J = 5.8 Hz, 2H), 1.35
s, 13H), 0.94 (d, J = 6.8 Hz, 3H); 13C NMR (126 MHz, CDCl3)
209.76, 173.06, 161.25, 140.61, 137.61,
28.99, 128.64, 117.28, 116.15, 115.22, 106.30, 43.18, 32.08, 29.70, 29.49, 24.83, 24.38, 22.86, 20.96, 14.28;
δ
−
+
◦
m/z calcd for C H BrNO [M + H] 408.1174, found 408.1335; Mp: 75.0–76.8 C.
20
27
3
3
.5. Evaluation of Antibacterial Activity
The antibacterial activity method was modified from the Manual of Antimicrobial Susceptibility
Testing, American Society of Microbiology [37]. The minimum inhibitory concentrations (MICs) of each
synthesized quinolone against Staphylococcus aureus (ATCC 6538P) and Escherichia coli (ATCC 25922)
were determined using resazurin-96 well plate microdilution assay. Briefly, the quinolone solutions
were prepared by dissolving the synthesized compounds in 4% v/v dimethyl sulfoxide (DMSO) in
Mueller-Hinton Broth (MHB) to obtain the concentrations of 2000, 1000, 500, 250, 125, and 62.5 µg/mL.
Ciprofloxacin, an antibiotic in the fluoroquinolone class, was used as a positive control. The 4% MHB
solutions with and without bacteria were also used as experimental controls. The bacterial cultures
◦
were prepared by growing each strain in MHB at 37 C for 3–5 h. Then, bacterial densities were
measured by spectrometry at OD 600 nm (Genesys 20, Thermo Scientific, Waltham, MA, USA) and
adjusted the cell concentration to 1.15
prepared quinolone solution was added into each well of 96-well plates, following by addition of 50 mL
bacterial solution, so the final concentrations of the tested compounds were 1000, 500, 250, 125, 62.5, and
×
106 cells/mL. To test the antibacterial activity, 50 mL of each
3
1.25
µ
g/mL. Then, the 96-well plates were closed, wrapped with parafilm to prevent the dehydration,
◦
and incubated at 37 C for 21 h. After incubating for 21 h, 30 mL of 0.015 w/v resazurin aqueous
solution was added into each well followed by 37 C incubation for 1 h. The lowest concentrations of
◦
the agents that displayed blue color (no color change of resazurin) were assigned as MIC values.
In order to investigate whether the synthesized quinolones could kill the bacteria or not, the
minimum bactericidal concentration (MBC) tests were performed by streaking the contents obtained
◦
from the wells appearing in a blue color on a Nutrient Agar (NA) medium and incubating at 37 C for
24 h. The MBC values were defined as the lowest concentrations that the bacteria could not grow on
the culture medium.

Molecules 2020, 25, 3059
10 of 12
3
.6. Evaluation of Antifungal Activity
The broth microdilution method for non-dermatophyte molds was performed to observe the
antifungal activity using 96-well plates in RPMI media according to CLSI M38 (2017) [38]. In addition,
4
1
×
10 spores of Aspergillus flavus ATCC204304 were utilized and co-incubated with amphotericin
B, a fungicidal antifungal agent, in serial dilutions, i.e., 0.125–8
µg/mL (final concentrations),
and different quinolone agents dissolved in DMSO in serial dilutions, i.e., 0.39–100
concentrations), at 37 C. XTT (sodium 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)-
µ
g/mL (final
◦
carbonyl]-2H-tetrazolium) solution (0.5 mg/mL in PBS) was then added into each well to observe the
◦
growth of A. flavus ATCC204304 at 48 h [39]. The plate was further incubated for 15 min at 37 C and
the supernatant was collected to measure the OD at 490 nm using a spectrophotometer (Lambda 1050+
UV/Vis/NIR, PerkinElmer, Waltham, MA, USA). The half maximal inhibitory concentration (IC ) of
50
each quinolone agent was then calculated using linear regression analyses. The experiments were
performed in biological triplicates.
4
. Conclusions
In summary, ten 3-alkyl-4-hydroxy-2-quinolone analogs (3a
–
3j), as well as the isomer 4d, were
synthesized and fully characterized. Most of the compounds showed substantial antifungal activity
against A. flavus. The introduction of substituents, especially for halogens, at C-6 and C-7 led to a
significant increase in the antifungal activity. The activity was also enhanced when replacing the
tridecyl group at C-3 with the nonyl group. The SAR knowledge obtained from this study might
be crucial for the development of new antimicrobial agents based on the 4-hydroxy-2-quinolone
privilege scaffold.
Supplementary Materials: The following are available online, spectroscopic data for compounds 1a
3j 4d 5d, Figure S1: MIC determination of Ciprofloxacin against S. aureus, Figure S2: MIC determination
of 3a−3h against S. aureus, Figure S3: MIC determination of 3i 3j and 4d against S. aureus, Figure S4: MBC
determination of 3i and 3j against S. aureus, Figure S5: MIC determination of Ciprofloxacin against E. coli, Figure
–1g, 2a, 2b,
3
a
–
,
,
,
S6: MIC determination of 3a−3h Ciprofloxacin against E. coli, Figure S7: MIC determination of 3i
, 3j and 4d
against E. coli.
Author Contributions: Conceptualization, T.K. (Tanatorn Khotavivattana); Data curation, T.K. (Tanatorn
Khotavivattana); Formal analysis, A.T. and S.N.P.; Funding acquisition, T.K. (Thitiphong Khamkhenshorngphanuch)
and T.K. (Tanatorn Khotavivattana); Investigation, T.K. (Thitiphong Khamkhenshorngphanuch), K.K., A.J., N.P. and
K.M.; Methodology, T.K. (Thitiphong Khamkhenshorngphanuch), A.T., S.N.P. and T.K. (Tanatorn Khotavivattana);
Project administration, T.K. (Tanatorn Khotavivattana); Resources, A.T., S.N.P. and T.K. (Tanatorn Khotavivattana);
Validation, T.K. (Thitiphong Khamkhenshorngphanuch), A.T., S.N.P. and T.K. (Tanatorn Khotavivattana); Visualization,
T.K. (Thitiphong Khamkhenshorngphanuch), A.T., S.N.P. and T.K. (Tanatorn Khotavivattana); Writing—original draft,
K.K., A.J. and T.K. (Tanatorn Khotavivattana); Writing—review & editing, T.K. (Thitiphong Khamkhenshorngphanuch),
A.T., S.N.P. and T.K. (Tanatorn Khotavivattana). All authors have read and agreed to the published version of
the manuscript.
Funding: This research was funded by Thailand Research Fund and the Office of the Higher Education
Commission, Research Grant for New Scholar, grant number [MRG6280024] (to T.K.) and Chulalongkorn
University, Grants for Development of New Faculty Staff, Ratchadaphiseksomphot Endowment Fund, grant
number [DNS62_081_23_014_2] (to T.K.).
Acknowledgments: The authors would like to thank the National Science and Technology Development Agency
(NSTDA), Pathum Thani 12120, Thailand for the high-resolution mass spectrum (HRMS) analysis.
Conflicts of Interest: The authors declare no conflict of interest.
References
1
.
Aslam, B.; Wang, W.; Arshad, M.I.; Khurshid, M.; Muzammil, S.; Rasool, M.H.; Nisar, M.A.; Alvi, R.F.;
Aslam, M.A.; Qamar, M.U.; et al. Antibiotic Resistance: A Rundown of a Global Crisis. Infect. Drug. Resist.
2
018, 11, 1645–1658. [CrossRef] [PubMed]
2
.
Aldo, T.; Rino, R. Changing Priorities in Vaccinology: Antibiotic Resistance’. Front. Immunol. 2018, 9, 1068.

Molecules 2020, 25, 3059
11 of 12
3.
4.
5.
Pekarski, O.; Björk, J.; Hedlund, G.; Andersson, G. The Inhibitory Effect in Experimental Autoimmune
Encephalomyelitis by the Immunomodulatory Drug Linomide (PNU-212616) Is Not Mediated via Release of
Endogenous Glucocorticoids. Autoimmunity 1998, 28, 235–241. [CrossRef] [PubMed]
Katagi, M.; Bolakatti, G.; Badiger, A.; Satyanarayana, D.; Mamledesai, S.; Sujatha, M. Synthesis, Spectral
Characterization and Antimicrobial Activity of Substituted Thiazolyl Derivatives of 2-Quinolones. Drug Res.
2
013, 63, 53–59. [CrossRef]
Bolakatti, G.; Katagi, M.S.; Sn, M.; Ml, S.; Dabadi, P.; Miskin, N. Synthesis and Antimicrobial Activity of
4
-Hydroxy-1-Methyl/Phenyl-3-(Substituted Anilinoacetyl) Quinolin-2(1H)-One. Rguhs J. Pharm. Sci. 2012, 2,
6
0–66. [CrossRef]
6
7
.
.
Hassanin, H.M.; El-Edfawy, S.M. Novel Heterocyclic Derivatives of 2-Quinolinone Associated with
Antibacterial and Antitumor Potencies. Heterocycles 2012, 85, 2421. [CrossRef]
Hassan, M.M.; Hassanin, H.M. An Efficient New Route for the Synthesis of Some 3-Hterocyclylquinolinones
via Novel 3-(1,2-Dihydro-4-hydroxy-1-methyl-2-oxoquinolin-3-yl)-3-oxopropanal and Their Antioxidant
Screening. J. Heterocycl. Chem. 2017, 54, 3321–3330. [CrossRef]
8
9
1
1
.
Muhammad, A.; Munawar, A.M.; Makshoof, A. Synthetic and Antibact. Studies of Quinolinylchalcones.
J. Appl. Chem. 2007, 7, 1620–1625.
Munawar, A.M.; Muhammad, A.; Hamid, L.S.; Faiz-ul, H.N. Synthesis and Antimicrobial Studies of Some
Quinolinylpyrimidine Derivatives. J. Chin. Chem. Soc. 2008, 55, 394–400. [CrossRef]
.
0. Magdy, A.I.; Hany, M.H.; Youssef, A.A. Synthesis, Characterization, and Antimicrobial Evaluation of Some
Novel 4-Hydroxyquinolin-2(1H)-ones. Synth. Commun. 2014, 44, 3470–3482.
1. Wenjie, X.; Xueyao, L.; Guixing, M.; Hongmin, Z.; Ya, C.; Johannes, K.; Jie, X.; Song, W. N-thiadiazole-
4
-hydroxy-2-quinolone-3-carboxamides bearing heteroaromatic rings as novel antibacterial agents: Design,
synthesis, biological evaluation and target identification. Eur. J. Med. Chem. 2020, 188, 112022.
2. Ukita, T.; Mizuno, D.I.; Tamura, T.; Yamakawa, T.; Nojima, S. The Antibacterial Properties of ompounds
Containing the Tricarbonylmethane Group. II-III. Yakugaku Zasshi 1951, 71, 234–243. [CrossRef]
3. Rho, T.C.; Bae, E.-A.; Kim, D.-H.; Oh, W.K.; Kim, B.Y.; Ahn, J.S.; Lee, H.S. Anti-Helicobacter Pylori Activity of
Quinolone Alkaloids from Evodiae Fructus. Biol. Pharm. Bull. 1999, 22, 1141–1143. [CrossRef]
1
1
1
4. Hamasaki, N.; Ishii, E.; Tominaga, K.; Tezuka, Y.; Nagaoka, T.; Kadota, S.; Kuroki, T.; Yano, I. Highly Selective
Antibacterial Activity of Novel Alkyl Quinolone Alkaloids from a Chinese Herbal Medicine, Gosyuyu
(Wu-Chu-Yu), Against Helicobacter Pylori In Vitro. Microbiol. Immunol. 2000, 44, 9–15. [CrossRef] [PubMed]
1
5. Guzman, J.D.; Wube, A.; Evangelopoulos, D.; Gupta, A.; Hufner, A.; Basavannacharya, C.; Rahman, M.;
Thomaschitz, C.; Bauer, R.; McHugh, T.D.; et al. nteraction of N-methyl-2-alkenyl-4-quinolones with
ATP-dependent MurE ligase of Mycobacterium tuberculosis: Antibacterial activity, molecular docking and
inhibition kinetics. J. Antimicrob. Chemother. 2011, 66, 1766–1772. [CrossRef]
1
6. Abdel-Ghani, A.A.; Amaal, A.A. Synthesis and study of antimicrobial agents of newly 6-nitro-4-hydroxy-2-
quinolone derivatives. Arch. Appl. Sci. Res. 2012, 4, 1339–1344.
1
7. Ukrainets, I.V.; Bevz, O.V.; Mospanova, E.V.; Savchenkova, L.V.; Yankovich, S.I. 4-Hydroxy-2-Quinolones. 202*.
Synthesis, Chemical and Biological Properties of 4-Hydroxy-6,7-Dimethoxy-2-Oxo-1,2-Dihydroquinoline-
3
-Carboxylic Acid Alkylamides. Chem. Heterocycl. Compd. 2012, 48, 320–326. [CrossRef]
1
8. Jampilek, J.; Musiol, R.; Pesko, M.; Kralova, K.; Vejsova, M.; Carroll, J.; Coffey, A.; Finster, J.; Tabak, D.;
Niedbala, H.; et al. Ring-Substituted 4-Hydroxy-1H-Quinolin-2-Ones: Preparation and Biological Activity.
Molecules 2009, 14, 1145–1159. [CrossRef]
1
2
2
9. Appelbaum, P.; Hunter, P. The Fluoroquinolone Antibacterials: Past, Present and Future Perspectives. Int. J.
Antimicrob. Agents 2000, 16, 5–15. [CrossRef]
0. Al-Hiari, Y.; Al-Mazari, I.; Shakya, A.; Darwish, R.; Abu-Dahab, R. Synthesis and Antibacterial Properties of
New 8-Nitrofluoroquinolone Derivatives. Molecules 2007, 12, 1240–1258. [CrossRef]
1. Jönsson, S.; Andersson, G.; Fex, T.; Fristedt, T.; Hedlund, G.; Jansson, K.; Abramo, L.; Fritzson, I.;
Pekarski, O.; Runström, A.; et al. Synthesis and Biological Evaluation of New 1,2-Dihydro-4-Hydroxy-2-Oxo-
3
-Quinolinecarboxamides for Treatment of Autoimmune Disorders: Structure
−
Activity Relationship. J. Med.
Chem. 2004, 47, 2075–2088. [CrossRef] [PubMed]
2
2. Tomassoli, I.; Herlem, G.; Picaud, F.; Benchekroun, M.; Bautista-Aguilera, O.M.; Luzet, V.; Jimeno, M.-L.;
Gharbi, T.; Refouvelet, B.; Ismaili, L. Synthesis, Regioselectivity, and DFT Analysis of New Antioxidant
Pyrazolo[4,3-c]Quinoline-3,4-Diones. Monatsh. Chem. 2016, 147, 1069–1079. [CrossRef]

Molecules 2020, 25, 3059
12 of 12
2
2
2
2
2
3. Greef, T.F.A.D.; Nieuwenhuizen, M.M.L.; Stals, P.J.M.; Fiti
é
, C.F.C.; Palmans, A.R.A.; Sijbesma, R.P.; Meijer, E.W.
The Influence of Ethylene Glycol Chains on the Thermodynamics of Hydrogen-Bonded Supramolecular
Assemblies in Apolar Solvents. Chem. Comm. 2008, 36, 4306. [CrossRef] [PubMed]
4. Banu, S.; Bollu, R.; Naseema, M.; Gomedhika, P.M.; Nagarapu, L.; Sirisha, K.; Kumar, C.G.; Gundasw, S.K.
A Novel Templates of Piperazinyl-1,2-Dihydroquinoline-3-Carboxylates: Synthesis, Anti-Microbial
Evaluation and Molecular Docking Studies. Bioorg. Med. Chem. Lett. 2018, 28, 1166–1170. [CrossRef]
5. Coppola, G.M.; Hardtmann, G.E. The Chemistry of 2H-3,1-Benzoxazine-2,4(1H)Dione (Isatoic Anhydride). 7.
Reactions with Anions of Active Methylenes to Form Quinolines. J. Heterocycl. Chem. 1979, 16, 1605–1610.
[CrossRef]
6. Basak, A.; Abouelhassan, Y.; Huigens, R.W. Halogenated quinolines discovered through reductive amination
with potent eradication activities against MRSA, MRSE and VRE biofilms. Org. Biomol. Chem. 2015, 13,
1
0290–10294. [CrossRef]
7. Luan, G.; Hong, Y.; Drlica, K.; Zhao, X. Suppression of reactive oxygen species accumulation accounts for
paradoxical bacterial survival at high quinolone concentration. Antimicrob. Agents Chemother. 2018, 62,
e01622-17. [CrossRef]
2
8. Hong, Y.; Li, Q.; Gao, Q.; Xie, J.; Huang, H.; Drlica, K.; Zhao, X. Reactive oxygen species play a dominant role
in all pathways of rapid quinolone-mediated killing. J Antimicrob Chemother. 2020, 75, 576–585. [CrossRef]
9. Spiccia, N.; Basutto, J.; Jokisz, P.; Wong, L.S.-M.; Meyer, A.G.; Holmes, A.B.; White, J.M.; Ryan, J.H. 1,3-Dipolar
Cycloaddition-Decarboxylation Reactions of an Azomethine Ylide with Isatoic Anhydrides: Formation of
Novel Benzodiazepinones. Org. Lett. 2011, 13, 486–489. [CrossRef]
2
3
0. Beutner, G.L.; Kuethe, J.T.; Yasuda, N. A Practical Method for Preparation of 4-Hydroxyquinolinone Esters.
J. Org. Chem. 2007, 72, 7058–7061. [CrossRef]
3
1. Stelzer, A.C.; Frazee, R.W.; Huis, C.V.; Cleary, J.; Opipari, A.W.; Glick, G.D.; Al-Hashimi, H.M. NMR Studies of
an Immunomodulatory Benzodiazepine Binding to Its Molecular Target on the Mitochondrial F1F0-ATPase.
Biopolymers 2010, 93, 85–92. [CrossRef] [PubMed]
3
3
3
3
3
2. Goetz, E.H.; Gabor, K.; Oskar, R.P. The chemistry of 2H-3,1-benzoxazine-2,4(1H)dione (isatoic anhydrides) 1.
The synthesis of N-substituted 2H-3,1-benzoxazine-2,4(1H)diones. J. Heterocycl. Chem. 1975, 12, 565–572.
3. Canonne, P.; Boulanger, R.; Chantegrel, B. Reactions of α,ω-Bis(Bromomagnesio)Alkanes with Heterocyclic
Anhydrides. Tetrahedron 1987, 43, 663–668. [CrossRef]
4. Matsuo, K.; Kimura, M.; Kinuta, T.; Takai, N.; Tanaka, K. Syntheses and Antimicrobial Activities of
-Acyltetramic Acid Derivatives. Chem. Pharm. Bull. 1984, 32, 4197–4204. [CrossRef]
3
5. Zou, X.; Jia, X.; Wang, X.; Xie, G. Substitution of Acyl for Acetyl with N-Acylbenzotriazoles Catalyzed by
Samarium Triiodide. Synth. Commun. 2007, 37, 1617–1625. [CrossRef]
6. Liang, Z.; Hua, F.; Renzhong, F.; Yuyang, J.; Yefun, Z. Efficient Copper-Catalyzed Synthesis of
N-Alkylanthranilic Acids via an ortho-Substituent Effect of the Carboxyl Group of 2-Halobenzoic Acids at
Room Temperature. Adv. Synth. Catal. 2009, 351, 1671–1676.
37. Cavalieri, S.J.; Harbeck, R.J.; McCarter, Y.S.; Ortez, J.H.; Rankin, I.D.; Sautter, R.L.; Sharp, S.E.; Spiegel, C.A.
Manual of Antimicrobial Susceptibility Testing; American Society of Microbiology: Washington, DC, USA, 2005.
38. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing
of Filamentous Fungi, 3rd ed.; Approved Standard; CLSI document M38-A3: Pennsylvania, PA, USA, 2017.
39. Van de Sande, W.W.; Tavakol, M.; van Vianen, W.; Bakker-Woudenberg, I.A. The effects of antifungal agents
to conidial and hyphal forms of Aspergillus fumigatus. Med. Mycol. 2010, 48, 48–55. [CrossRef]
Sample Availability: Samples of the compounds 3a–3j and 4d are available from the authors.
©
2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
CC BY) license (http://creativecommons.org/licenses/by/4.0/).
(